Trading a NAMS straddle lets you take a pure volatility position on NewAmsterdam Pharma Company NV without committing to a direction. NewAmsterdam Pharma Company NV's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate NAMS straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on NAMS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when NewAmsterdam Pharma Company NV stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the NAMS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the NAMS straddle is the cleanest expression of that view. Our scanner prices every NAMS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a NAMS straddle into a catalyst or short a NAMS straddle to harvest decay, the options straddle setups that matter are all in one place.
